ANNEXON, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
ANNEXON, INC. (ANNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $4.53 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2026-08-12
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2026-03-31 was $4.26, a 23.12% increase year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2025-03-31 was $3.46, a 35.08% decline year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2024-03-31 was $5.33, a 3.09% decline year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2023-03-31 was $5.50, a 28.48% decline year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2025 was $3.06, a 42.16% decline from fiscal 2024.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2024 was $5.29, a 6.70% decline from fiscal 2023.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2023 was $5.67, a 23.07% decline from fiscal 2022.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2022 was $7.37.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.53 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $4.26 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $3.06 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $3.08 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $3.11 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $3.46 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $5.29 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $5.29 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $5.29 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $5.33 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $5.67 10-K · filed 2024-03-26 | |||
| 2023-09-30 | $5.58 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $5.43 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $5.50 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $7.37 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $8.04 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $8.04 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $7.69 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |